Antinuclear antibodies in progressive systemic sclerosis

P. Riboldi, R. Asero, L. Origgi, S. Crespi, P. L. Meroni, C. Sguotti, M. G. Sabbadini

Research output: Contribution to journalArticlepeer-review


Sera from 84 patients with progressive systemic sclerosis (PSS) were tested for the presence of antinuclear antibodies by immunofluorescence on HEp2 cells and gel immunodiffusion. Fluorescent antinuclear antibodies were detected in 80 subjects with PSS (95%). Ninety-three percent of patients with CREST syndrome and 3% of those with diffuse scleroderma had a centromere staining. Precipitating antibodies were found in 57% of PSS sera and identified as anti-Scl 70 in 42 cases (50%). This specificity was found in 42 of 70 subjects with diffuse scleroderma (60%); another patient was positive for anti-nRNP antibodies, and 5 more sera from PSS patients showed precipitin lines of unknown specificity. No serum from 14 patients with CREST syndrome was positive for anti-Scl 70 antibodies. Significant relationships have been found between centromere staining and CREST syndrome (p <0.0005) and between the presence of anti-Scl 70 antibodies and the diffuse form of scleroderma (p <0.0005). The latter specificity is strongly associated with the grainy speckled pattern on HEp2 fluorescence (p <0.0005). These data suggest that anti-Scl 70 antibodies and anti-centromere antibodies are useful markers for different subgroups of patients with PSS.

Original languageEnglish
Pages (from-to)205-211
Number of pages7
JournalClinical and Experimental Rheumatology
Issue number3
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Rheumatology
  • Immunology


Dive into the research topics of 'Antinuclear antibodies in progressive systemic sclerosis'. Together they form a unique fingerprint.

Cite this